Luigi Coltelli1,2,#, Paola Orlandi3,#, Chiara Finale1,4,#, Gianna Musettini1,4,#, Luna Chiara Masini1,4, Marco Scalese5, Giulia Soria1,4, Elena Sartori1,4, Ylenia Nodari1,4, Giada Arrighi1,2, Arianna Bandini3, Marta Banchi3, Costanza Tacchi3, Donghao Tang3, Barbara Salvadori6, Lucia Tanganelli1,7, Simona Giovannelli1,8, Mirco Pistelli9, Samanta Cupini1,4, Maurizio Lucchesi1,10, Alessandro Cosimi11, Giulia Lorenzini1,7, Elisa Biasco1,4, Chiara Caparello1,4, Giulia Acconci1,4,6, Eloise Fontana1,4, Eleonora Bona1,4, Azzurra Farnesi1,4, Antonio Pellino1,4, Andrea Marini1,4, Ermelinda De Maio1,4, Irene Stasi1,4, Cecilia Barbara1,4, Enrico Sammarco1,4, Javier Rosada12,13, Giacomo Allegrini1,4,*, Guido Bocci3,*
Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.073799
- 22 April 2026
Abstract Background: The treatment of advanced hormone receptor-positive (HR+) breast cancer has seen relevant changes in last years. However, bevacizumab remains an option when combined with paclitaxel, but no certified pharmacogenetic profiles are now usable for the prediction of its response in breast cancer patients. This study aimed to explore the pharmacogenetic interactions among single nucleotide polymorphisms (SNPs) of genes involved in the angiogenic process and their impact on progression-free survival (PFS) and overall survival (OS) in hormone receptor-positive (HR+) metastatic breast cancer subjects administered with bevacizumab plus paclitaxel, or with paclitaxel alone (clinicaltrial.gov… More >